Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 18,047 shares, a growth of 100.7% from the December 15th total of 8,994 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily volume of 107,685 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 107,685 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Zacks Research downgraded shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, Wall Street Zen raised Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $26.50.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ CMMB opened at $1.77 on Thursday. The stock’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $3.08. The firm has a market capitalization of $10.90 million, a PE ratio of -0.60 and a beta of 0.51. Chemomab Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $8.80.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.